Mesenchymal stem cells in Parkinson's disease: Motor and nonmotor symptoms in the early posttransplant period.
Mesenchymal stem cells
Motor symptoms
Nonmotor symptoms
Journal
Surgical neurology international
ISSN: 2229-5097
Titre abrégé: Surg Neurol Int
Pays: United States
ID NLM: 101535836
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
04
2020
accepted:
20
10
2020
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
8
1
2021
Statut:
epublish
Résumé
Treatment of patients with Parkinson disease (PD) using autologous mesenchymal stem cells (MSCs) is a promising method to influence the pathogenesis of the disease. The aim of this study was to assess the immediate results of the introduction of MSCs on the effectiveness of motor and nonmotor symptoms in patients with PD. MSCs were transplanted to 12 patients with PD through intravenous and tandem (intranasal + intravenous) injections. Effectiveness of the therapy was evaluated 1 and 3 months posttransplantation. Neurological examination of the intensity of motor symptoms was carried out in the morning after a 12 or 24 h break in taking antiparkinsonian drugs, then 1 h after they were taken. The intensity of motor symptoms was assessed with the help of Section III of the Unified PD Rating Scale of the International Society for Movement Disorders (UPDRS). The intensity of nonmotor symptoms was assessed with the help of the following scales: Hamilton Depression Rating Scale, the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale, Nonmotor Symptoms Scale, and the 39-item Parkinson's Disease Questionnaire. We found a statistically significant decrease in the severity of motor and nonmotor symptoms in the study group in the posttransplant period. Positive results allow us to consider MSCs transplantation as a disease-modifying therapeutic strategy in PD. However, this method of PD treatment is not a fully understood process, which requires additional studies and a longer follow-up period to monitor the patients' condition posttransplantation.
Sections du résumé
BACKGROUND
BACKGROUND
Treatment of patients with Parkinson disease (PD) using autologous mesenchymal stem cells (MSCs) is a promising method to influence the pathogenesis of the disease. The aim of this study was to assess the immediate results of the introduction of MSCs on the effectiveness of motor and nonmotor symptoms in patients with PD.
METHODS
METHODS
MSCs were transplanted to 12 patients with PD through intravenous and tandem (intranasal + intravenous) injections. Effectiveness of the therapy was evaluated 1 and 3 months posttransplantation. Neurological examination of the intensity of motor symptoms was carried out in the morning after a 12 or 24 h break in taking antiparkinsonian drugs, then 1 h after they were taken. The intensity of motor symptoms was assessed with the help of Section III of the Unified PD Rating Scale of the International Society for Movement Disorders (UPDRS). The intensity of nonmotor symptoms was assessed with the help of the following scales: Hamilton Depression Rating Scale, the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale, Nonmotor Symptoms Scale, and the 39-item Parkinson's Disease Questionnaire.
RESULTS
RESULTS
We found a statistically significant decrease in the severity of motor and nonmotor symptoms in the study group in the posttransplant period.
CONCLUSION
CONCLUSIONS
Positive results allow us to consider MSCs transplantation as a disease-modifying therapeutic strategy in PD. However, this method of PD treatment is not a fully understood process, which requires additional studies and a longer follow-up period to monitor the patients' condition posttransplantation.
Identifiants
pubmed: 33408914
doi: 10.25259/SNI_233_2020
pii: SNI-11-380
pmc: PMC7771400
doi:
Types de publication
Journal Article
Langues
eng
Pagination
380Informations de copyright
Copyright: © 2020 Surgical Neurology International.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
PLoS One. 2016 Oct 20;11(10):e0164762
pubmed: 27764160
Biosci Rep. 2015 Apr 28;35(2):
pubmed: 25797907
Lancet Neurol. 2012 Feb;11(2):150-6
pubmed: 22236384
J Vasc Interv Radiol. 2010 Apr;21(4):443-51
pubmed: 20346882
Transl Res. 2010 Feb;155(2):62-70
pubmed: 20129486
Arthritis Rheum. 2002 Dec;46(12):3349-60
pubmed: 12483742
World J Stem Cells. 2016 Mar 26;8(3):73-87
pubmed: 27022438
Science. 1979 May 11;204(4393):643-7
pubmed: 571147
Cytotherapy. 2012 Jan;14(1):56-60
pubmed: 21954839
Stem Cells. 2010 Jun;28(6):1099-106
pubmed: 20506226
Mayo Clin Proc. 2019 May;94(5):892-905
pubmed: 31054608
Front Aging Neurosci. 2016 May 31;8:117
pubmed: 27303288
Biol Psychiatry. 2016 Mar 1;79(5):402-414
pubmed: 26392130
BMC Neurosci. 2010 Apr 26;11:52
pubmed: 20420688
Stem Cells. 2017 Jun;35(6):1446-1460
pubmed: 28316123
J Immunol Res. 2015;2015:394917
pubmed: 25961059
J Neurosci Res. 2017 Mar;95(3):907-917
pubmed: 27617772
Stem Cells Int. 2012;2012:931902
pubmed: 22550521
J Neuroinflammation. 2014 Aug 04;11:135
pubmed: 25088370
Cell Transplant. 2017 Sep;26(9):1551-1559
pubmed: 29113472
Front Cell Neurosci. 2016 May 02;10:109
pubmed: 27199663
J Neuroinflammation. 2014 Sep 03;11:149
pubmed: 25182840
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
J Clin Invest. 2013 Jan;123(1):272-84
pubmed: 23202734
J Biomed Sci. 2016 Nov 4;23(1):76
pubmed: 27809910
Stem Cells Dev. 2008 Jun;17(3):547-54
pubmed: 18513164
Neurosci Lett. 2006 Mar 6;395(2):124-8
pubmed: 16359791
Mov Disord. 2008 Apr 15;23(5):690-9
pubmed: 18228568
Exp Ther Med. 2017 Mar;13(3):976-982
pubmed: 28450929
Cell Transplant. 2018 Feb;27(2):325-334
pubmed: 29637820
Stem Cells Int. 2013;2013:130763
pubmed: 24194766
Cell Transplant. 2010;19(2):203-17
pubmed: 19906332
Stem Cells. 2006 Apr;24(4):1030-41
pubmed: 16253981